|Title||Review of the safety and efficacy of ustekinumab.|
|Publication Type||Journal Article|
|Year of Publication||2010|
|Authors||Scherl EJ, Kumar S, Warren RU|
|Journal||Therap Adv Gastroenterol|
|Date Published||2010 Sep|
Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.
|Alternate Journal||Therap Adv Gastroenterol|
|PubMed Central ID||PMC3002587|
Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.